innate pharma

Clinical trials with lacutamab

June 2022

PARIS: IPH.PA NASDAQ: IPHA





Lacutamab in Cutaneous T Cell Lymphoma

innate pharma

Lacutamab

First-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody

- Lacutamab under development for the treatment of various forms of T-cell lymphomas (TCL)
- Compelling Phase 1 data in Sézary syndrome (SS), published in *Lancet Oncology*
- EMA PRIME and FDA Fast Track designations for Sézary Syndrome (SS) patients who have received at least two prior systemic therapies
- Orphan drug designation in the EU and US for the treatment of cutaneous TCL (CTCL)
- Development strategy:
  - Fast to market strategy in SS
  - Expansion in other forms of T-cell lymphomas: mycosis fungoides (MF) and peripheral T-cell lymphoma (PTCL)



Phase 1 – Completed

FDA Fast Track Designation granted based on these results

Total 44 patients with CTCL ≥ 2 lines of therapy

- 25 (incl. 20 SS) in dose escalation (intra-patient dose escalation was allowed)
- 19 (incl. 15 SS) in cohort expansion

Recommended Phase 2 Dose: 750mg QW x 4 then Q2W x 10 then Q4W until progression

Safety:

- Maximum tolerated dose was not reached
- No DLT[1]s. Most common AE[2]: lymphopenia, fatigue (mostly grade 1–2)

More info on: clinicaltrials.gov

Sézary Syndrome Subgroup (n=35)



	All SS N=35	SS without LCT N=28	Prior mogamulizumab N=7
Best global response	**42.9%**	**53.6%**	**42.9%**
DOR	13.8	13.8	13.8
PFS	11.7	12.8	16.8

[1]DLT = dose limiting toxicity
[2]AE = adverse event

TELLOMAK Phase 2 Study in Two CTCL Subtypes - ongoing

innate pharma

Sézary Syndrome (N~60) ≥ 2 prior systemic therapies	Mycosis Fungoides (N~100) ≥ 2 prior systemic therapies		
Cohort 1	**Cohort 2#**	**Cohort 3#**	**All Comers***
All comers, SS, must include mogalizumab as prior therapy	KIR3DL2+ Simon 2 Stage	KIR3DL2- Simon 2 Stage	KIR3DL2+/-
Enrollment ongoing; Preliminary data expected in H2 2022	*Cohort 2 advanced to Stage 2; Cohort 3 did not progress to Stage 2. Preliminary Stage 1 data presented in 2021. Preliminary data expected in H2 2022*		

STUDY ENDPOINTS

- Primary endpoint: objective response rate
- Key secondary endpoints: progression-free survival, duration of response, quality of life and adverse events

TARGET EXPRESSION

- KIR3DL2 +/expression is defined as ≥1% using central evaluation of KIR3DL2 by immunohistochemistry
- *FFPE based Companion Diagnostic under development
- # Frozen assay

More info on: clinicaltrials.gov

FFPE - formalin-fixed paraffin embedded

Encouraging Preliminary Results in KIR3DL2-Expressing MF Cohort of TELLOMAK Trial

Cohort 2 Overall response rate of ~35% in advanced patient population with no current standard of care*
Cohort 3 Overall response rate of ~11% KIR3DL2 non-expressors cohort did not progress to Stage 2*

Cohort 2
KIR3DL2 expressors



Skin (N = 17)

6 confirmed (1CR, 5PR) global responses
9 / 17 patients still ongoing therapy

Cohort 3
KIR3DL2 non expressors



Skin (N = 19)

2 confirmed global responses (2PR)
11 / 19 patients still ongoing therapy

* reported after data cut off (DCO) date, May 10, 2021. Bagot et al. ICML June 2021. Response rate reported after data cut off.
CR: complete response, PR: partial response, uPR: unconfirmed partial response

Developing a New Standard of Care Across KIR3DL2-Expressing T-Cell Lymphomas

Cutaneous T-Cell Lymphoma (CTCL)

Phase 2 TELLOMAK Trial

Sezary Syndome

80-200 patients
>90% KIR3DL2 expression

- Trial expanded (pivotal potential)
- Fast Track & PRIME Designation
- Preliminary data expected in 2022 (H2)

Mycosis Fungoides

2,200-4,400 patients
~50% KIR3DL2 expression

- Advanced Cohort 2 to Stage 2 with earlier-than-expected efficacy signal
- 2 active cohorts – KIR3DL2 expressing and all comers
- Reported preliminary Cohort 2, Stage 1 data at ICML – 35% ORR
- Preliminary data expected in 2022 (H2)

Peripheral T-Cell Lymphoma (PTCL)

Multi-trial Strategy From Relapsed to Frontline PTCL

~18,000 patients
~50% KIR3DL2 expression

- Monotherapy + combination with GemOX (LYSA) & SOC in relapsed setting
- Follow data into earlier lines (in combination with CHOP)

GemOX: gemcitabine and oxaliplatin SOC: Standard of care, CHOP: cyclophosphamide, hydroxydaunomycin, oncovin, prednisolone

Innate Clinical Trials

Learn more about our commitment to patients and our clinical trials at:

https://www.innate-pharma.com/products/clinical-trials

innate pharma



www.innate-pharma.com

PARIS: IPH.PA NASDAQ: IPHA